{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:08:44Z","timestamp":1790770124599,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,8,22]],"date-time":"2011-08-22T00:00:00Z","timestamp":1313971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Lund Institute of Technology (LTH)"},{"name":"Bioinvent International AB"},{"DOI":"10.13039\/100005189","name":"the Leukemia and Lymphoma Society","doi-asserted-by":"crossref","award":["R6189-09"],"award-info":[{"award-number":["R6189-09"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"crossref","award":["08\/0285"],"award-info":[{"award-number":["08\/0285"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"crossref","award":["09\/0390"],"award-info":[{"award-number":["09\/0390"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sm\u00e4rtafonden","award":["SSF\/09-05"],"award-info":[{"award-number":["SSF\/09-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Oncology"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>The transcription factor SOX11 is a novel diagnostic marker for mantle cell lymphoma (MCL), distinguishing this aggressive tumor from potential simulators. Recent data also show that the level of SOX11 correlates to in\u00a0vitro growth properties in MCL, as well as the clinical progression. We have previously shown that MCL\u2010associated pathways, such as Rb\u2010E2F, are dysregulated leading to decreased proliferation upon overexpression of SOX11, emphasizing the impact of SOX11 on MCL\u2010specific gene expression and growth control. However, it remains to be determined which growth regulatory pathways that are induced upon SOX11 knock\u2010down, leading to an increased cellular growth. Consequently, we established a model cell line with constitutive down\u2010regulation of SOX11. The highly proliferative features of this cell line were investigated by gene expression analysis, proliferation assay, cell cycle distribution and potential to induce tumors in NOD\u2010SCID mice. Our in\u00a0vitro studies demonstrated a SOX11\u2010dependent regulation of MCL\u2010specific gene expression. In addition, we identified autotaxin (ATX) to be regulated by SOX11. Our results clearly showed a correlation between SOX11 level and cellular growth rate, which was dependent on ATX, as well as a direct relation between the level of SOX11 in tumorigenic cells and the growth rate of these tumors in NOD\u2010SCID mice.<\/jats:p>","DOI":"10.1016\/j.molonc.2011.08.001","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T07:25:51Z","timestamp":1314084351000},"page":"527-537","source":"Crossref","is-referenced-by-count":27,"title":["Knock\u2010down of SOX11 induces autotaxin\u2010dependent increase in proliferation <i>in\u00a0vitro<\/i> and more aggressive tumors <i>in\u00a0vivo<\/i>"],"prefix":"10.1002","volume":"5","author":[{"given":"Paolo","family":"Conrotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Andr\u00e9asson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venera","family":"Kuci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl A.K.","family":"Borrebaeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.5858\/2003-127-0424-COMCLC"},{"key":"e_1_2_10_3_1","first-page":"629","article-title":"Autotaxin and lipid signaling pathways as anticancer targets","volume":"11","author":"Braddock D.T.","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.140"},{"key":"e_1_2_10_5_1","first-page":"5446","article-title":"Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate","volume":"63","author":"Clair T.","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.008474"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1385\/MN:29:3:213"},{"key":"e_1_2_10_8_1","first-page":"4398","article-title":"Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells","volume":"62","author":"Ek S.","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M600077-MCP200"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093401"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945008785132439"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.141911"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07835.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-187"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2007.12.041"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.213"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000059759"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2007.02.003"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.26.16050"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.03.027"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07325.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.08.026"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010264"},{"key":"e_1_2_10_25_1","first-page":"1337","article-title":"Dendritic cell-based therapy for mantle cell lymphoma","volume":"28","author":"Munger C.M.","year":"2006","journal-title":"Int. J. Oncol."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04687"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2009.03.001"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-068791"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2009.07.018"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2010.08.002"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0339-1"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.09.114"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.08.016"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200204026"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000030088.28684.5B"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2007.02.001"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-063958"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07329.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014085"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212211200"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.12.022"}],"container-title":["Molecular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.molonc.2011.08.001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.molonc.2011.08.001","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1574789111000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1574789111000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.molonc.2011.08.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:48:41Z","timestamp":1695494921000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1016\/j.molonc.2011.08.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,22]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1016\/j.molonc.2011.08.001"],"URL":"https:\/\/doi.org\/10.1016\/j.molonc.2011.08.001","archive":["Portico"],"relation":{},"ISSN":["1574-7891","1878-0261"],"issn-type":[{"value":"1574-7891","type":"print"},{"value":"1878-0261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,22]]}}}